Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature

Xu,Qiuyi; Xu,Nong; Fang,Weijia; Zhao,Peng; Mao,Chenyu; Zheng,Yulong; Mou,Haibo

doi:10.3892/ol.2013.1232

Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature

Authors:
- Qiuyi Xu
- Nong Xu
- Weijia Fang
- Peng Zhao
- Chenyu Mao
- Yulong Zheng
- Haibo Mou
View Affiliations

Affiliations: Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003 P.R. China
Published online on: March 6, 2013 https://doi.org/10.3892/ol.2013.1232
Pages: 1601-1604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary Fallopian tube carcinoma (PFTC) is a rare but highly aggressive disease. Currently, treatments are similar to those used in epithelial ovarian carcinoma (EOC), however, there are distinct differences between the two diseases. PFTC tends to recur in the retroperitoneal nodes and distant sites more often than EOC. Limited literature with regard to effective agents in platinum-resistant and -refractory (Pt-R) disease exists, particularly after two lines of consecutive treatment. In this case report, a 47-year-old female with PFTC exhibited recurrence in the liver after postoperative chemotherapy. The patient received paclitaxel and cisplatin combination as first‑line chemotherapy and topotecan as a second-line treatment, which is considered platinum-refractory. After the second‑line treatment failed, this patient received a gemcitabine plus cisplatin combination as third-line chemotherapy for a total of 6 cycles. The liver metastases regressed rapidly and completely. The patient's progression-free survival (PFS) was 10 months and overall survival (OS) was 45 months. In conclusion, gemcitabine and cisplatin combination is an effective regimen for refractory PFTC even after the failure of two previous lines of consecutive chemotherapy and this warrants further independent investigation.

View Figures

View References

1	Riska A, Leminen A and Pukkala E: Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953–97. Int J Cancer. 104:643–645. 2003.PubMed/NCBI
2	Markman M, Webster K, Zanotti K, Kulp B, Peterson G and Belinson J: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 90:593–596. 2003. View Article : Google Scholar : PubMed/NCBI
3	Lorusso D, Di Stefano A, Fanfani F and Scambia G: Role of gemcitabine in ovarian cancer treatment. Ann Oncol. 17(Suppl 5): v188–v194. 2006. View Article : Google Scholar : PubMed/NCBI
4	Stewart SL, Wike JM, Foster SL and Michaud F: The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol. 107:392–397. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ajithkumar TV, Minimole AL, John MM and Ashokkumar OS: Primary fallopian tube carcinoma. Obstet Gynecol Surv. 60:247–252. 2005. View Article : Google Scholar
6	Hefler LA, Rosen AC, Graf AH, et al: The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study. Cancer. 89:1555–1560. 2000. View Article : Google Scholar : PubMed/NCBI
7	Wethington SL, Herzog TJ, Seshan VE, et al: Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer. 113:3298–3306. 2008. View Article : Google Scholar : PubMed/NCBI
8	Rosen AC, Ausch C, Hafner E, et al: A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur J Cancer. 34:1725–1729. 1998.PubMed/NCBI
9	Riska A and Leminen A: Updating on primary fallopian tube carcinoma. Acta Obstet Gynecol Scand. 86:1419–1426. 2007. View Article : Google Scholar : PubMed/NCBI
10	Papadimitriou CA, Peitsidis P, Bozas G, et al: Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience. Oncology. 75:42–48. 2008. View Article : Google Scholar : PubMed/NCBI
11	Gadducci A, Landoni F, Sartori E, et al: Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol. 81:150–159. 2001. View Article : Google Scholar : PubMed/NCBI
12	Pectasides D, Pectasides E, Papaxoinis G, et al: Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol. 115:97–101. 2009. View Article : Google Scholar : PubMed/NCBI
13	Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG and Abeler VM: Carcinoma of the fallopian tube. Cancer. 89:2076–2084. 2000. View Article : Google Scholar : PubMed/NCBI
14	Tresukosol D, Kudelka AP, Edwards CL, Fromm GL, Mante R and Kavanagh JJ: Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel. Gynecol Oncol. 58:258–261. 1995. View Article : Google Scholar : PubMed/NCBI
15	Dunton CJ and Neufeld J: Complete response to topotecan of recurrent fallopian tube carcinoma. Gynecol Oncol. 76:128–129. 2000. View Article : Google Scholar : PubMed/NCBI
16	Matsuo K, Lin YG, Roman LD and Sood AK: Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 19:1339–1354. 2010. View Article : Google Scholar : PubMed/NCBI
17	van Moorsel CJ, Pinedo HM, Veerman G, et al: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer. 80:981–990. 1999.
18	Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S and Rodriguez M: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 88:17–21. 2003. View Article : Google Scholar : PubMed/NCBI
19	Nagourney RA, Brewer CA, Radecki S, et al: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 88:35–39. 2003. View Article : Google Scholar : PubMed/NCBI
20	Tewari D, Monk BJ, Hunter M, Falkner CA and Burger RA: Gemcitabine and cisplatin chemotherapy an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs. 22:475–480. 2004. View Article : Google Scholar : PubMed/NCBI
21	Brewer CA, Blessing JA, Nagourney RA, Morgan M and Hanjani P: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 103:446–450. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bozas G, Bamias A, Koutsoukou V, Efstathiou E, Gika D, Papadimitriou CA and Dimopoulos MA: Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol. 104:580–585. 2007. View Article : Google Scholar : PubMed/NCBI
23	Rose PG: Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer. 15(Suppl 1): 18–22. 2005. View Article : Google Scholar : PubMed/NCBI
24	Griffiths RW, Zee YK, Evans S, et al: Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer. 21:58–65. 2011. View Article : Google Scholar : PubMed/NCBI